Stanford University
Showing 41-50 of 1,603 Results
-
Jessica M. Allan
Adjunct Clinical Associate Professor, Pediatrics
BioDr. Jessie Allan, MD works as a Pediatric Hospitalist for Palo Alto Medical Foundation. She cares for patients in the Newborn Nursery, Intermediate Care Nursery, and on the inpatient wards at Stanford Children's Hospital. She serves as the chair-elect of the American Academy of Pediatrics, Section on Hospital Medicine.
-
Christopher Almond
Professor of Pediatrics (Cardiology)
BioChristopher Almond, MD, MPH is Professor of Pediatrics in the Division of Cardiology at the Stanford University School of Medicine where he is a board-certified pediatric cardiologist at Stanford's Lucile Packard Children's Hospital in Palo Alto, CA. His clinical and research interests are focused on pediatric heart failure, mechanical circulatory support, heart transplantation, and anticoagulation. He completed his training in pediatrics, cardiology, and a senior fellowship in heart failure/transplant at Boston Children's Hospital before before appointment as Assistant Professor of Pediatrics at Harvard Medical School/Boston Children’s Hospital. Dr. Almond completed his MPH at the Harvard School of Public Health with a focus on statistics and epidemiology (study design for rare diseases) followed by a Medical Device Fellowship at the FDA in the Division of Cardiovascular Devices at CDRH. Dr. Almond moved to Stanford in 2014 where he currently serves as professor of pediatrics and directs the clinical research program within Pediatric Advanced Cardiac Therapies (PACT) Program. He also serves as Medical Director of the Children’s Heart Center Anticoagulation Management Program at Stanford (CHAMPS). Dr. Almond has a passion for collaborative research serving as PI for federally-funded multi-center clinical trials including the Berlin Heart ventricular assist device (VAD) FDA Trial that led to its FDA approval in 2011, the TEAMMATE (everolimus for heart transplant) Trial, the TROLLEY (Cardiohelp ECMO/anticoagulation RCT in heart failure) Trial, the NHLBI PumpKIN (Jarvik 2015 LVAD) Trial, and the SPOT BIAS Trial, an FDA-funded trial to understand racial/pigment bias in commercial pulse oximeters.
-
Leina Alrabadi
Clinical Associate Professor, Pediatrics - Gastroenterology
BioI enjoy working with a multidisciplinary team to care for patients who have complex medical needs with the aim of giving children a better future. As a clinical researcher, my main focus is on finding improved therapies for autoimmune and cholestatic liver diseases, since an ideal therapy currently does not exist.
-
Dahham Alsoud, MD, MSc, PhD(c)
Affiliate, Pediatrics - Gastroenterology
Visiting Postdoctoral Scholar, Pediatrics - GastroenterologyBioDr. Alsoud is a physician-scientist conducting postdoctoral research at the Rosen Lab, supported by fellowships from the Belgian American Educational Foundation and the Stanford Medicine Children’s Health Center for IBD and Celiac Disease. His research combines advanced statistical modeling and bioinformatics, leveraging multi-omics and longitudinal clinical data from the CAPTURE IBD cohort to uncover the molecular and clinical determinants of therapeutic outcomes. Through this work, he aims to reduce reliance on trial-and-error treatment strategies, strengthen evidence-based clinical decision-making, and ultimately improve outcomes and quality of life for individuals living with inflammatory bowel disease.
After earning his MD from Damascus University, Dr. Alsoud conducted his PhD research at KU Leuven, where he integrated clinical prediction, serum proteomics, and whole-blood transcriptomics to investigate treatment heterogeneity, therapeutic resistance, and response to advanced therapies in IBD. He also holds a Master of Science in Health Care Management and Policy from KU Leuven, reflecting his broader interest in designing efficient, patient- and provider-centered models of healthcare delivery. Dr. Alsoud serves as an Editorial Fellow for Basic and Translational Science at Inflammatory Bowel Diseases and has contributed to the peer review of more than 150 manuscripts in the field. -
Manuel R. Amieva
Professor of Pediatrics (Infectious Diseases) and of Microbiology and Immunology
Current Research and Scholarly InterestsMy laboratory studies how bacteria colonize our bodies for long periods of time, and how interactions between bacteria and the epithelial surfaces of the gastrointestinal tract and skin may lead to disease. Epithelial surfaces are the first barrier against infection, but they also where our bodies meet and co-evolve with the microbial world.. Several of our studies have focused on the epithelial junctions as a target for bacterial pathogens. The host epithelium uses its epithelial junctions to form a tight but dynamic barrier with an external surface that is inhospitable to microbial attachment, secretes anti-microbial compounds, and has a rapid rate of self-renewal. The balance in the microbe-epithelial relationship results in silent commensalism or symbiosis; an imbalance results in diseases ranging from acute bacterial invasive disease to chronic ulcers or carcinoma.
Our laboratory has developed novel microscopy applications such as quantitative 3D confocal microscopy, electron microscopy, time-lapse imaging, microinjection and micromanipulation to visualize the interaction of pathogens with epithelial cells in culture and in animal and human tissues. Many of out studies focus on the gastric pathogen Helicobacter pylori, but we have also expanded our investigations to include the intestinal pathogens Listeria monocytogenes and Salmonella enterica, and the skin pathogen and colonizer Staphylococcus aureus. I believe that elucidating how microbes communicate with and alter our epithelial cells at a molecular level will be important for finding novel therapeutic targets to control mucosal colonization and prevent invasive disease.
Using this perspective, we have uncovered several novel concepts of how bacteria colonize and breach our epithelial surfaces. For example, we discovered that Helicobacter pylori target the intercellular junctions, and in particular that the virulence factor CagA affects junction assembly and cell polarity. This confers H. pylori the ability to extract nutrients and grow directly on the epithelial surface. We also found that these properties of CagA have consequences for cellular transformation of the epithelium. For instance, we showed that H. pylori affect the activity and state of epithelial stem cells in the stomach by colonizing the epithelial surface deep in the gastric glands. This gland-associated population is essential for pathological inflammation and hyperplasia in animal models, and confers significant colonization advantages to the bacteria. Our Listeria research uncovered a new mechanism and site where bacteria can breach the gastrointestinal epithelial barrier to invade. We found that Listeria find their receptor for invasion at sites of epithelial senescence, where the epithelial junctions undergo dynamic turnover. To study Salmonella and H. pylori we have developed a human organoid model to study their interactions with human gut epithelium in vitro. To study Staphylococcus aureus pathogenesis, we have developed methods to visualize infection at the scale of a single bacterial microcolony using an organoid culture system of human keratinocytes and fibroblasts that grow into a 3D skin-equivalent. We recently identified several proteins at the eptithelial junctions as host factors involved in the pathogenesis of one of Staphylococcus aureus major toxins. -
Michael Amylon
Professor of Pediatrics (Hematology/Oncology) at the Lucile Salter Packard Children's Hospital, Emeritus
Current Research and Scholarly InterestsBone marrow transplantation (BMT) is a treatment modality which is being broadly applied to a growing number of disorders. Increasing success with BMT is offering improved survival to pediatric and adult patients with acute leukemia, chronic leukemia, lymphomas, and a variety of solid tumors as well as severe aplastic anemia.
